Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes -: implications for cost-effectiveness analyses

被引:75
|
作者
van Valkengoed, IGM
Morré, SA
van den Brule, AJC
Meijer, CJLM
Bouter, LM
Boeke, AJP
机构
[1] Vrije Univ Amsterdam Med Ctr, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Sect Mol Pathol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Immunogenet Lab, Amsterdam, Netherlands
[4] PAMM Inst, Lab Pathol & Med Microbiol, Eindhoven, Netherlands
关键词
mass screening; Chlamydia trachomatis; salpingitis; pelvic inflammatory disease; infertility; costs and cost analysis; ectopic pregnancy;
D O I
10.1093/ije/dyh029
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Cost-effectiveness analyses of screening programmes for asymptomatic Chlamydia trachomatis infection suggest that screening at low prevalences in the population is cost-effective. However, the decision models in these studies are based on assumptions about the risk of complications, which are derived from the literature. Incorrect assumptions may lead to under- or overestimation of the effectiveness of screening. The first objective of this paper is to evaluate the assumptions about the probability of complications after an asymptomatic C. trachomatis infection. The second objective is to calculate alternative rates by using available data on the incidence of complications. Methods We identified cost-effectiveness studies via Medline, and evaluated these for the evidence for the quoted probabilities. In addition, the probability of complications was calculated for Amsterdam from available registration data. Results In the three studies that were identified, the assumptions for the rates of pelvic inflammatory disease (PID) (clinical and subclinical) after C. trachomatis infection varied from 15% to 80%, and for ectopic pregnancy, tubal factor infertility, and chronic pelvic pain after PID from 5-25%, 10-20%, and 18-30%, respectively. The assumptions were based on data from high-risk populations, case-control data, and data not accounting for misdiagnoses. Using data obtained from local registrations, we estimated the probability of a clinical PID (0.43%), ectopic pregnancy (0.07%), and tubal factor infertility (0.02%) for women with a current infection. These estimates were consistently lower than the estimates based on the literature. Conclusions We argue that an overestimation of the current complication rates is likely. The effect of overestimation is potentially the greatest in populations with a low prevalence, since the currently assumed cost savings associated with screening may disappear when using more realistic estimates for complications.
引用
收藏
页码:416 / 425
页数:10
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF CULTURE AND DIRECT ANTIGEN TESTING FOR CHLAMYDIA TRACHOMATIS IN 2 THEORETICAL POPULATIONS
    NETTLEMAN, MD
    JONES, RB
    CLINICAL RESEARCH, 1986, 34 (04): : A912 - A912
  • [42] TREATMENT FAILURE HAS IMPORTANT IMPLICATIONS FOR CHLAMYDIA TRANSMISSION AND THE EFFECTIVENESS OF SCREENING PROGRAMMES
    Regan, D. G.
    Wilson, D. P.
    Hocking, J. S.
    SEXUALLY TRANSMITTED INFECTIONS, 2013, 89 : A266 - A266
  • [43] METAANALYSIS ADJUSTING FOR NONCOMPLIANCE - IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSES
    GLASZIOU, PP
    IRWIG, LM
    MEDICAL DECISION MAKING, 1990, 10 (04) : 325 - 325
  • [44] Cost-effectiveness analysis of screening adolescent males for chlamydia on admission to detention
    Blake, DR
    Gaydos, CA
    Quinn, TC
    SEXUALLY TRANSMITTED DISEASES, 2004, 31 (02) : 85 - 95
  • [45] Cost effectiveness of home based population screening for Chlamydia trachomatis in the UK:: economic evaluation of chlamydia screening studies (ClaSS) project
    Roberts, Tracy E.
    Robinson, Suzanne
    Barton, Pelham M.
    Bryan, Stirling
    McCarthy, Anne
    Macleod, John
    Egger, Matthias
    Low, Nicola
    BMJ-BRITISH MEDICAL JOURNAL, 2007, 335 (7614): : 291 - 294A
  • [46] Mind the costs, too: towards better cost-effectiveness analyses of PBF programmes
    Chi, Y-Ling
    Gad, Mohamed
    Bauhoff, Sebastian
    Chalkidou, Kalipso
    Megiddo, Itamar
    Ruiz, Francis
    Smith, Peter
    BMJ GLOBAL HEALTH, 2018, 3 (05):
  • [47] Optimal Control and Cost-Effectiveness Analysis of an HPV–Chlamydia trachomatis Co-infection Model
    A. Omame
    C. U. Nnanna
    S. C. Inyama
    Acta Biotheoretica, 2021, 69 : 185 - 223
  • [48] COST-EFFECTIVENESS OF SEROLOGY AND CELL-CULTURE FOR CHLAMYDIA-TRACHOMATIS IN LOW PREVALENCE WOMEN
    NETTLEMAN, M
    JONES, R
    ROBERTS, S
    DITTUS, R
    CLINICAL RESEARCH, 1986, 34 (02): : A527 - A527
  • [49] COST-EFFECTIVENESS OF CULTURING FOR CHLAMYDIA-TRACHOMATIS - A STUDY IN A CLINIC FOR SEXUALLY-TRANSMITTED DISEASES
    NETTLEMAN, MD
    JONES, RB
    ROBERTS, SD
    KATZ, BP
    WASHINGTON, AE
    DITTUS, RS
    QUINN, TS
    ANNALS OF INTERNAL MEDICINE, 1986, 105 (02) : 189 - 196
  • [50] Why Colorectal Cancer Screening Programmes in Europe are of Sub-Optimal Intensity: A Systematic Review of Cost-Effectiveness Analyses
    Pokharel, Rajani
    Lin, Yishu
    McFerran, Ethna
    O'Mahony, James Francis
    MEDICAL DECISION MAKING, 2024, 44 (02) : NP120 - NP120